Fractyl Health, Inc. (NASDAQ:GUTS) Stock Short Interest Falls 87.7%

by · The Markets Daily

Fractyl Health, Inc. (NASDAQ:GUTS – Get Free Report) saw a significant drop in short interest in October. As of October 15th, there was short interest totaling 265,311 shares, a drop of 87.7% from the September 30th total of 2,150,590 shares. Approximately 2.2% of the company’s stock are short sold. Based on an average trading volume of 218,634 shares, the short-interest ratio is currently 1.2 days.

Hedge Funds Weigh In On Fractyl Health

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Fractyl Health in the second quarter valued at about $1,431,000. Bank of America Corp DE bought a new position in Fractyl Health during the 2nd quarter worth approximately $4,791,000. General Catalyst Group Management LLC bought a new position in Fractyl Health during the 2nd quarter worth approximately $3,880,000. Pale Fire Capital SE lifted its holdings in Fractyl Health by 84.5% during the 1st quarter. Pale Fire Capital SE now owns 5,921,045 shares of the company’s stock worth $2,711,000 after buying an additional 2,711,103 shares during the last quarter. Finally, Nantahala Capital Management LLC acquired a new position in shares of Fractyl Health in the 2nd quarter worth approximately $8,968,058.

Fractyl Health Stock Down 18.5%

GUTS traded down $0.20 during trading on Tuesday, hitting $0.87. The company had a trading volume of 798,444 shares, compared to its average volume of 338,117. Fractyl Health has a 1-year low of $0.87 and a 1-year high of $29.34. The company has a debt-to-equity ratio of 1.41, a current ratio of 3.15 and a quick ratio of 3.15. The company has a market cap of $11.56 million, a PE ratio of -0.08 and a beta of 2.42. The business has a 50-day moving average of $6.18 and a 200-day moving average of $8.62.

Fractyl Health (NASDAQ:GUTS – Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The company reported ($1.44) earnings per share for the quarter, topping the consensus estimate of ($1.62) by $0.18. As a group, analysts forecast that Fractyl Health will post -6.32 earnings per share for the current year.

Analysts Set New Price Targets

GUTS has been the topic of several recent analyst reports. Weiss Ratings cut Fractyl Health from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Morgan Stanley reduced their price target on Fractyl Health to $4.00 and set an “equal weight” rating for the company in a report on Monday, October 19th. Wall Street Zen lowered Fractyl Health from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Finally, Craig Hallum set a $5.00 price objective on Fractyl Health in a report on Monday, October 19th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Fractyl Health currently has a consensus rating of “Hold” and an average price target of $50.25.

Read Our Latest Stock Report on Fractyl Health

About Fractyl Health

(Get Free Report)

Fractyl Health, Inc is a biotechnology company focused on developing therapies for metabolic diseases, including obesity and type 2 diabetes. The company aims to create treatments that address the underlying biology of these conditions and provide longer-lasting alternatives to frequently administered medicines.

Fractyl Health’s technology platforms include Revita, an endoscopic procedure designed to modify the lining of the duodenum and potentially improve metabolic function, and a gene therapy platform intended to enable the body to produce therapeutic levels of metabolic hormones such as glucagon-like peptide-1 (GLP-1).

Further Reading